TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38962571

Group type: EXPERIMENTAL
Intervention: Medically Assisted Reproduction (MAR) for men
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Medically Assisted Reproduction (MAR) for women
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Ectopic pregnancies in women with PCD
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Infertility prevalence in men with PCD
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Infertility prevalence in women with PCD
Number of subjects: 265
Study: 38962958

Group type: EXPERIMENTAL
Intervention: Gamified intervention with a support partner
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n = 50) setting step goals and receiving daily feedback
Number of subjects: 94
Study: 38963325

Group type: EXPERIMENTAL
Intervention: Measurement of handgrip strength (HGS) with Jamar dynamometers and feedback about normal values for age and sex.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard check-ups (control group).
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Measurement of HGS and feedback to patients with T2DM.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Patients with low inclusion HGS.
Number of subjects: 334
Study: 38963459

Group type: EXPERIMENTAL
Intervention: Abiraterone 1000 mg once daily
Number of subjects: 81
Study: 38963477

Group type: EXPERIMENTAL
Intervention: Video group psychoeducational intervention delivered in Spanish, including a video testimonial and facilitated discussion.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interviews with participants.
Number of subjects: 19
Study: 38963556

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention
Number of subjects: 614

Group type: COMPARATOR
Intervention: Baseline SCr/Q-height and SCr/Q-age
Number of subjects: 614
Study: 38963583

Group type: EXPERIMENTAL
Intervention: Autologous blood (AB) injection: 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) injection: 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined injection (AB + CS): 1 ml each of autologous venous blood and 40 mg methylprednisolone acetate along with 1 ml of 2% prilocaine HCl
Number of subjects: 120
Study: 38963656

Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 94
Study: 38963694

Group type: EXPERIMENTAL
Intervention: CV-based video analysis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Human-CV collaboration
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CV-based analysis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of early and late EEA videos
Number of subjects: 46
Study: 38963799

Group type: EXPERIMENTAL
Intervention: Lesional skin of CSU patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nonlesional skin of CSU patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 38963866

Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control details not available
Number of subjects: 0
Study: 38964203

Group type: EXPERIMENTAL
Intervention: Total urinary polyphenols (TPE)
Number of subjects: 662
Study: 38964333

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (LDRT) plus immune checkpoint inhibitors (ICI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Concurrent thoracic LDRT plus chemoimmunotherapy
Number of subjects: 15
Study: 38964353

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 38964361

Group type: EXPERIMENTAL
Intervention: V116 (21-valent pneumococcal conjugate vaccine)
Number of subjects: 2663

Group type: COMPARATOR
Intervention: PCV20 (active comparator)
Number of subjects: 2663
Study: 38964420

Group type: EXPERIMENTAL
Intervention: Fazirsiran 25 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fazirsiran 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fazirsiran 200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fazirsiran
Number of subjects: 40
Study: 38964630

Group type: EXPERIMENTAL
Intervention: Early Social Intervention (ESI)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Joint Attention Symbolic Play Engagement and Regulation (JASPER)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study: 38964794

Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy with double flap technique (LPG-DFT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Laparoscopic total gastrectomy with Roux-en-Y (LTG-RY)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: LPG-DFT
Number of subjects: 216
Study: 38964797

Group type: EXPERIMENTAL
Intervention: Higher patient-to-nurse ratio
Number of subjects: 217714
Study: 38964799

Group type: EXPERIMENTAL
Intervention: Low-dose, non-contrast-enhanced thoracic CT scans
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Rapid molecular sputum analysis using the BIOFIRE® FILMARRAY® pneumonia
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard microbiological processing alone (no FAPP)
Number of subjects: 220
Study: 38964803

Group type: EXPERIMENTAL
Intervention: HPV self-testing
Number of subjects: 0
Study: 38964802

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) integrated with conventional bronchoscopy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional bronchoscopy without nCLE
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 208
Study: 38964845

Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound diagnosis of isolated RAA
Number of subjects: 309
Study: 38964854

Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (C-EMR)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (H-EMR)
Number of subjects: 177
Study: 38965031

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy (LDL-C goal of 50-70 mg/dl)
Number of subjects: 822

Group type: COMPARATOR
Intervention: High-intensity statin therapy
Number of subjects: 822
Study: 38965184

Group type: EXPERIMENTAL
Intervention: Subjective evaluations of safety of the participant's current social and physical environment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Objective measures of neighborhood-level disorder
Number of subjects: 286
Study: 38965462

Group type: EXPERIMENTAL
Intervention: Intracavernous injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 8
Study: 38965464

Group type: EXPERIMENTAL
Intervention: Mindful walking intervention (24 sessions over 3 months)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Delayed mindful walking group (control)
Number of subjects: 114
Study: 38965499

Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard training (active control)
Number of subjects: 40
Study: 38965541

Group type: EXPERIMENTAL
Intervention: Single-inhaler triple therapy (SITT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smart inhalers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SITT with digital support through a smart inhaler and an e-health platform
Number of subjects: 300

Group type: COMPARATOR
Intervention: Multi-inhaler triple therapy (MITT)
Number of subjects: 300
Study: 38965550

Group type: EXPERIMENTAL
Intervention: SRP followed by erythritol subgingival air polishing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SRP followed by diode laser application
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 24
Study: 38965566

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) for ME/CFS
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (CPET) for CTL
Number of subjects: 84

Group type: COMPARATOR
Intervention: Matched case-control pairs (n = 55) for aerobic capacity, age, and sex
Number of subjects: 84
Study: 38965587

Group type: EXPERIMENTAL
Intervention: TTT + TA + QA
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Implementation activities completed
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Perceived positive characteristics of the Body Project
Number of subjects: 63
Study: 38965611

Group type: EXPERIMENTAL
Intervention: Injection of 40 mg of furosemide intravenously over 10 minutes after fURS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Injection of 40 mg of furosemide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual treatment with an alpha-blocker
Number of subjects: 100

Group type: COMPARATOR
Intervention: Imaging analysis by urologist
Number of subjects: 100
Study: 38965612

Group type: EXPERIMENTAL
Intervention: Concept-guided, personalised, motor-cognitive exergame training (twice per week for 30 to 40 minutes)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care without additional intervention(s)
Number of subjects: 38
Study: 38965976

Group type: EXPERIMENTAL
Intervention: APS+HIVST
Number of subjects: 3646

Group type: COMPARATOR
Intervention: Standard APS
Number of subjects: 3646
Study: 38966081

Group type: EXPERIMENTAL
Intervention: Exergame-based motor-cognitive training on a labile surface
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stable surface training (Control Group)
Number of subjects: 30
Study: 38966095

Group type: EXPERIMENTAL
Intervention: Routine amoxicillin
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study: 38966255

Group type: EXPERIMENTAL
Intervention: Decreases in internalized weight stigma (IWS) at week 20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial reductions in internalized weight stigma (IWS)
Number of subjects: 0
Study: 38966802

Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS) combined with cognitive Virtual Reality Rehabilitation System (VRRS)
Number of subjects: 109

Group type: COMPARATOR
Intervention: placebo tDCS combined with VRRS
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: cognitive TR
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: at-home unstructured cognitive stimulation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: cognitive treatment as usual
Number of subjects: 109
Study: 38966851

Group type: EXPERIMENTAL
Intervention: 2 mg Moxidectin (MOX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 150 µg/kg Ivermectin (IVM)
Number of subjects: 72
Study: 38966990

Group type: EXPERIMENTAL
Intervention: Macitentan plus tadalafil combination therapy
Number of subjects: 148
Study: 38967389

Group type: EXPERIMENTAL
Intervention: Adolescent only (AO) exercise intervention
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Adolescent + Parent (A + P) exercise intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both AO and A + P arms
Number of subjects: 116
Study: 38967583

Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI) use
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Private health insurance
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: >16 educational years
Number of subjects: 73
Study: 38967589

Group type: EXPERIMENTAL
Intervention: Simtuzumab
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Pro-C3 and ELF score
Number of subjects: 234
Study: 38967722

Group type: EXPERIMENTAL
Intervention: Ultrasensitive detection method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38967884

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 38967926

Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management (CDCM) for 6 months
Number of subjects: 308
Study: 38967927

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Temporal change in EtCO2
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Slope of EtCO2
Number of subjects: 1113
Study: 38967929

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic formulation consisting of 8 strains from 5 different genera
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 38968138

Group type: EXPERIMENTAL
Intervention: NKTR-255 with CAR19-22
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 11

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 11
Study: 38968243

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (supervised exercise with laser-guided feedback and interferential current therapy); 8 treatment sessions (twice per week) over 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 31
Study: 38968400

Group type: EXPERIMENTAL
Intervention: Painful neuropathy (probable or definite NeuP)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Machine learning (random forest)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Random forest
Number of subjects: 1181
Study: 38968414

Group type: EXPERIMENTAL
Intervention: LQ cut-off criterion of +/-60 for mixed-handedness
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Analysis of hand preference and hand performance data
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Need for a consensus on mathematical determination of ambidexterity
Number of subjects: 600
Study: 38968425

Group type: EXPERIMENTAL
Intervention: Ultrabrief Right Unilateral ECT with Frontoparietal Electrode Placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrabrief Right Unilateral ECT with Temporoparietal Electrode Placement
Number of subjects: 0
Study: 38968520

Group type: EXPERIMENTAL
Intervention: Anlotinib maintenance therapy
Number of subjects: 23
Study: 38968568

Group type: EXPERIMENTAL
Intervention: PSMA PET imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSMA histopathology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSMA-targeted therapeutics
Number of subjects: 0
Study: 38968599

Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Number of subjects: 45
Study: 38968807

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (NFB) from the superior temporal gyrus (STG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham-controlled neurofeedback from the motor cortex
Number of subjects: 22
Study: 38968827

Group type: EXPERIMENTAL
Intervention: Speckle tracking technology for lung sliding quantification
Number of subjects: 30
Study: 38969081

Group type: EXPERIMENTAL
Intervention: Participants with PAD (ABI ≤0.90)
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Participants without PAD (normal ABIs)
Number of subjects: 2209
Study: 38969242

Group type: EXPERIMENTAL
Intervention: HOPE-treated donor livers (DBD)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: HOPE-treated donor livers (DCD)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Graft loss due to PNF (DBD)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Graft loss due to IC (DBD)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Graft loss due to PNF (DCD)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Graft loss due to IC (DCD)
Number of subjects: 1202
Study: 38969374

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg, max 50 mg) over 40 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.5 mL/kg normal saline, max 50 mL) over 40 minutes
Number of subjects: 20
Study: 38969378

Group type: EXPERIMENTAL
Intervention: Soothing cream gel (SCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 38969497

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1395
Study: 38969791

Group type: EXPERIMENTAL
Intervention: Rash management guide provided to patients in Apa-RP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased vigilance and proactive management
Number of subjects: 0
Study: 38969866

Group type: EXPERIMENTAL
Intervention: siRNA and small molecule inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chicken embryo chorioallantoic membrane (CAM) model
Number of subjects: 0
Study: 38969879

Group type: EXPERIMENTAL
Intervention: Metronomic vinorelbine (NVB) monotherapy (n=11)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NVB plus anti-PD-1 toripalimab (n=7)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Anti-angiogenic bevacizumab, NVB and toripalimab (n=27)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Conventional cisplatin, NVB and toripalimab (n=26)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n=26)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: VEX cohort (n=26)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Bevacizumab cohort (n=27)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cisplatin cohort (n=26)
Number of subjects: 97
Study: 38969921

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: AAPPO
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: SF-36v2
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: SALT
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: PGI-C
Number of subjects: 612
Study: 38969919

Group type: EXPERIMENTAL
Intervention: Somapacitan 5 mg/1.5 mL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Somapacitan 10 mg/1.5 mL
Number of subjects: 33

Group type: COMPARATOR
Intervention: Somapacitan 5 mg/1.5 mL and Somapacitan 10 mg/1.5 mL
Number of subjects: 33
Study: 38969987

Group type: EXPERIMENTAL
Intervention: Multi-component implementation strategies including identifying clinic champions, development/distribution of patient educational materials, developing and implementing quality monitoring systems, and convening clinical meetings.
Number of subjects: 180
Study: 38970004

Group type: EXPERIMENTAL
Intervention: Conventional open-tray impressions CII (splinted pick-up)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Digital implant impressions DII with TRIOS 3 Shape intraoral scanner
Number of subjects: 8
Study: 38970008

Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) calculated as log10 (TG/HDL)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: AIP as a predictor of GDM
Number of subjects: 585
Study: 38970037

Group type: EXPERIMENTAL
Intervention: Real-time ambulatory assessments using a wrist-worn actigraphy device and electronic ecological momentary assessment for perceived discrimination, microaggression, and stress.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous blood pressure monitoring through a wristband.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-collected saliva samples for cortisol level assessment.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fasting venous blood sample for lab assessments.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neighborhood-level built environmental and social environmental characteristics based on participants' addresses.
Number of subjects: 80
Study: 38970065

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminoglycoside + Ciprofloxacin
Number of subjects: 0
Study: 38970070

Group type: EXPERIMENTAL
Intervention: Data-informed platform for health intervention
Number of subjects: 120
Study: 38970127

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg once/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg twice/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg three times/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 38970237

Group type: EXPERIMENTAL
Intervention: Gunshot wounds
Number of subjects: 163

Group type: COMPARATOR
Intervention: Bomb blast wounds
Number of subjects: 163
Study: 38970256

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg twice daily + Temozolomide (TMZ) 60 mg once daily pulsed (7-day schedule)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Pamiparib + TMZ
Number of subjects: 139
Study: 38970327

Group type: EXPERIMENTAL
Intervention: RSVPreF3 co-administered with FLU-D-QIV
Number of subjects: 1415

Group type: COMPARATOR
Intervention: FLU-D-QIV alone
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Co-administration of RSVPreF3 and FLU-D-QIV
Number of subjects: 1415
Study: 38970425

Group type: EXPERIMENTAL
Intervention: Timrepigene emparvovec (gene therapy), up to 0.1 mL containing 1 × 10^11 vg/mL, administered bilaterally and sequentially.
Number of subjects: 0
Study: 38970585

Group type: EXPERIMENTAL
Intervention: Primary antegrade wiring (AW)
Number of subjects: 12136

Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting machine learning model
Number of subjects: 12136
Study: 38970587

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 400
Study: 38970593

Group type: EXPERIMENTAL
Intervention: RF-CL model
Number of subjects: 4371

Group type: EXPERIMENTAL
Intervention: CACS-CL model
Number of subjects: 4371

Group type: COMPARATOR
Intervention: Basic PTP model
Number of subjects: 4371

Group type: EXPERIMENTAL
Intervention: RF-CL and CACS-CL models
Number of subjects: 4371
Study: 38970665

Group type: EXPERIMENTAL
Intervention: Personalised nutrition feedback based on new sustainable healthy eating guidelines
Number of subjects: 20

Group type: COMPARATOR
Intervention: Existing healthy eating guidelines (control)
Number of subjects: 20
Study: 38970708

Group type: EXPERIMENTAL
Intervention: MRI training protocol (customized booklet, MRI toy set, mock scanner)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments (MABC, TVIP, ABAS, BRIEF, CBCL, NIH Toolbox Flanker, NIH Toolbox Pattern Comparison, WPPSI)
Number of subjects: 57